Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the individualization of therapy in patients with...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sabrina Chiloiro, Marialuisa Appetecchia, Antonio Bianchi, Denise Costa, Christine De Acetis, Patrizia Gargiulo, Antonella Giampietro, Andrea M Isidori, Marie-Lise Jaffrain-Rea, Marina Passeri, Francesca Pigliaru, Maurizio Poggi, Laura De Marinis
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BioExcel Publishing Ltd 2024-05-01
Ráidu:	Drugs in Context
Fáttát:	acromegaly diabetes mellitus growth hormone igf1 pasireotide-lar somatotropinoma
Liŋkkat:	https://www.drugsincontext.com/long-term-pasireotide-lar-treatment-in-the-personalized-therapy-of-patients-with-complex-acromegaly-a-collection-of-clinical-experiences/
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!